Inclusion Criteria:

  -  Patient must have a pathologically-confirmed diagnosis of non-small cell lung cancer
     (NSCLC).

  -  Patient must have advanced disease, defined as IIIB (not amenable to definitive
     multi-modality therapy), IIIC, or IV (includes local or distant recurrent disease
     after a prior diagnosis of Stage I-III disease). All staging is via the American
     Joint Committee on Cancer (AJCC)/International Association for the Study of Lung
     Cancer (IASLC) 8th edition staging criteria.

  -  Patient tumor must have somatic activating sensitizing mutation in EGFR (e.g., but
     not limited to Exon 19 deletion, L858R, E709X, G719X, exon 19 insertions, L861Q,
     S768I). Patients with non-sensitizing mutations in EGFR (EGFR exon 20 insertions)
     are not eligible. Plasma, cytology, or tumor tissue can be utilized for standard of
     care mutation testing.

  -  Prior chemotherapy and/or immunotherapy administered as primary treatment for NSCLC
     before EGFR mutation was identified is allowed ≤ 45 days of study registration to
     allow for return of sequencing information.

  -  Prior treatment with osimertinib administered as primary treatment for NSCLC is
     allowed ≤ 30 days of study registration (prior treatment with any other EGFR TKI
     agent is not allowed).

  -  Patient must not be participating in EA5182 or any other cancer treatment trial.
     Osimertinib or osimertinib + chemotherapy/immunotherapy given as first-line
     treatment for this disease cannot be given as part of a clinical trial.

  -  Patients that have received prior radiation therapy in any setting for this disease
     are eligible.

  -  Adults age ≥ 18 years.

This study tests the feasibility of using real-world data collection through the
recruitment of well-characterized patients into a registry, spanning academic and
community practice sites to determine patient outcomes in all-comers. The scientific
community would further benefit from a greater understanding of the safety and
effectiveness of newly approved therapies prescribed in routine clinical practice.

Non-interventional (observational) study with 250 participants per exposure group
(maximum accrual up to 538 total participants) comparing outcomes in patients with
EGFR-mutated NSCLC, not being treated in a clinical trial but receiving standard of care
osimertinib +/- chemotherapy.

The treating physician determines whether a patient will receive standard of care single
agent osimertinib or osimertinib with chemotherapy and the planned treatment is recorded
at registration.

Clinical/Imaging assessments will be per the treating physician.